End of single drug therapy in sight, says Pharnext
This article was originally published in Scrip
Having signed a validating first partnership deal with Ipsen, Pharnext hopes the pharmaceutical industry will feel more able to embrace the French start up's vision that the age of single drug therapy is over, chief executive Professor Daniel Cohen told Scrip.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.